検索結果

irment, resulting in less than 0.1 in decimal visual acuity(1) . However, no guidelines or evidence-based therapies have been established anywhere in the world for CRAO(2) . Senju will work diligently...

Management Policy | About Senju | SENJU Pharmaceutical

and a lofty aspiration, creates new value and provides happiness beyond society's expectations based on our management policy. In accomplishing this aim, we focus on "Five Basic Styles"...

学会発表実績 | 研究開発活動 | 千寿製薬株式会社

a TRPV1 antagonist, a novel treatment for dry eye disease, on body temperature and ECG – evaluation based on non-clinical studies. Kotaro Yamada1, Yoshinori Yamagiwa1, Keiko Imaida2, Shigeki Matsumoto...

製品開発方針 | 研究開発活動 | 千寿製薬株式会社

122(8) : 549-57  #5: Nakagawa T, Tokuda Y, Nakano M, Komori Y, Hanada N, Tourtas T, et al. RNA-Seq-based transcriptome analysis of corneal endothelial cells derived from patients with Fuchs endotheli...

Business Activities | About Senju | SENJU Pharmaceutical

Based on a sense of mission to contribute to the health of the eyes of people around the world, and a development policy that puts top priority on safety, we have always taken a pioneering path in oph...